Loading patent…
AssigneeACC Therapeutics Inc
InventorsBing-Hua Jiang, Jing Fang
Estimating the term…
Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers. Thus, our results indicate that apigenin can be applied to various human cancers for chemoprevention, and for chemotherapy when combined with other therapeutic reagents.
A method of inhibiting, treating, or reducing the incidence of pre-malignant lesions of ovarian cancer (ovarian cancer chemoprevention) by administering to women, a pharmaceutical composition of a compound (apigenin or apigenin derivatives) represented by the structure of formula (A), pharmaceutically acceptable salt and hydrate, its N-oxide, ester, or any combination formula. The Structure A compound alone or in combination with other agents can be used with pharmaceutical composition of Structure A compound in the range of about 0.3 to 4 mg/kg body weight each time.
A method of decreasing and suppressing the occurrence of pre-malignant lesions of prostate cancer (cancer chemoprevention) by administering to men, a pharmaceutical composition of a Structure A compound (apigenin or apigenin derivatives) in the form of pharmaceutically acceptable salt and hydrate, its N-oxide, ester, or any combination formula. The Structure A compound alone or in combination with other agents can be used for prostate cancer prevention with pharmaceutical composition of Structure A compound in the range of about 0.3 to 4 mg/kg body weight each time.
A method of inhibiting or treating malignant lesions of ovarian cancer (ovarian cancer chemotherapy) by administering to women, a pharmaceutical composition of a Structure A compound (apigenin or apigenin derivatives) represented by pharmaceutically acceptable salt and hydrate, its N-oxide, ester, or any combination formula. The Structure A compound alone can be used with pharmaceutical composition of Structure A compound in the range of about 0.3 to 4 mg/kg body weight each time.
A method of decreasing and inhibiting the occurrence of prostate cancer (cancer chemotherapy) by administering to men, a pharmaceutical composition of a Structure A compound (apigenin or apigenin derivatives) in the form of pharmaceutically acceptable salt and hydrate, its N-oxide, ester, or any combination formula. The Structure A compound alone can be used for prostate cancer treatment with pharmaceutical composition of Structure A compound in the range of about 0.3 to 4 mg/kg body weight each time.
Dependencies are inferred from the claim text.